Data from ongoing FIREFISH study confirm long-term efficacy and safety profile of Evrysdi in children…
Company announcement – No. 26 / 2023 Total number of shares and voting rights in…
Company announcement – No. 26 / 2023 Total number of shares and voting rights in…
First–and–only approved FcRn antagonist for gMG patients by NMPA 68% of anti-AChR antibody positive gMG…
First–and–only approved FcRn antagonist for gMG patients by NMPA 68% of anti-AChR antibody positive gMG…
The Federal Institute for Drugs and Medical Devices in Germany granted the Company approval to…
The Federal Institute for Drugs and Medical Devices in Germany granted the Company approval to…
-Improvements in Left Ventricular Ejection Fraction (LVEF) for the Majority of Patients Suggest Preservation of…
-Improvements in Left Ventricular Ejection Fraction (LVEF) for the Majority of Patients Suggest Preservation of…
REDMOND, Wash.–(BUSINESS WIRE)–Data I/O Corporation (NASDAQ:DAIO), the leading global provider of advanced security and data…
Technology Executive Hong Q. Hou Joins Semtech to Help Oversee Next Era of Growth CAMARILLO,…
SUGAR LAND, Texas–(BUSINESS WIRE)–Researched by Industrial Info Resources — The energy transition is apparent in…
LONG BEACH, Calif.–(BUSINESS WIRE)–California Resources Corporation (NYSE: CRC) plans to release its second-quarter 2023 financial…
DALLAS–(BUSINESS WIRE)–IOG Resources Management (“IRM”), the management company responsible for managing IOG Resources, LLC (“IOGR…
Insider threat can be described as the potential of an employee to utilize their authorised…
IRVINE, Calif., June 30, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical…
IRVINE, Calif., June 30, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical…
MALVERN, Pa., June 30, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ:…
MALVERN, Pa., June 30, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ:…
Divested assets to include Xiidra®, on-market treatment for dry eye disease and SAF312 (libvatrep), potential…